Alector (NASDAQ:ALEC) CFO Sells $77,807.66 in Stock

Alector, Inc. (NASDAQ:ALEC) CFO Neil Berkley sold 29,251 shares of the firm’s stock in a transaction that occurred on Thursday, September 3rd. The stock was sold at an average price of $2.66, for a total transaction of $77,807.66. Following the sale, the chief financial officer owned 350,649 shares of the company’s stock, valued at $932,726.34. This represents a 7.70% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Alector Price Performance

ALEC stock opened at $2.46 on Monday. Alector, Inc. has a one year low of $1.09 and a one year high of $3.40. The firm has a market cap of $274.68 million, a PE ratio of -2.24 and a beta of 0.65. The firm’s 50 day moving average price is $1.91 and its 200-day moving average price is $2.06. The company has a debt-to-equity ratio of 0.80, a quick ratio of 5.26 and a current ratio of 5.26.

Alector (NASDAQ:ALEC) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.02. The company had revenue of $3.32 million during the quarter, compared to analyst estimates of $1.71 million. Alector had a negative return on equity of 531.03% and a negative net margin of 850.13%. On average, equities research analysts anticipate that Alector, Inc. will post -0.87 EPS for the current year.

Analysts Set New Price Targets

Separately, Weiss Ratings raised Alector from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 13th. Three research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $3.62.

Institutional Investors Weigh In On Alector

Institutional investors have recently modified their holdings of the company. Jane Street Group LLC lifted its stake in Alector by 4.7% during the 1st quarter. Jane Street Group LLC now owns 256,551 shares of the company’s stock worth $316,000 after acquiring an additional 11,618 shares in the last quarter. Strs Ohio purchased a new position in Alector during the 1st quarter valued at about $126,000. Geode Capital Management LLC grew its position in Alector by 1.0% in the 2nd quarter. Geode Capital Management LLC now owns 1,982,068 shares of the company’s stock valued at $2,775,000 after acquiring an additional 19,970 shares in the last quarter. Prudential Financial Inc. purchased a new stake in Alector during the second quarter worth about $30,000. Finally, XTX Topco Ltd increased its stake in Alector by 125.2% during the second quarter. XTX Topco Ltd now owns 73,338 shares of the company’s stock worth $103,000 after purchasing an additional 40,767 shares during the period. 85.83% of the stock is owned by institutional investors and hedge funds.

Alector Company Profile

Alector is a clinical-stage biotechnology company headquartered in South San Francisco, California. Founded in 2013, the company is focused on discovering and developing immuno-neurology therapies that target the innate immune system to treat a range of neurodegenerative disorders. Alector’s approach aims to harness the body’s natural defense mechanisms to clear pathological proteins and restore neuronal function in conditions such as Alzheimer’s disease and frontotemporal dementia.

The company’s pipeline includes multiple product candidates in both preclinical and clinical stages, with lead programs AL001 and AL002 advancing in frontotemporal dementia and Alzheimer’s disease studies.